ASCO 2016 - J-ALEX Trial: Should Alecensa Replace Xalkori as first-Line ALK Therapy

H. Jack West, MD, Founder, President and CEO

GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-ALEX trial and whether Alecensa should replace Xalkori as a first-line ALK therapy.

 

 

 


GRACE would like to thank the following sponsors for their support of this program

 

Video Language: 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation